Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint

HONG KONG, March 23, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ("CORXEL"). Under the agreement, the Company has acquired the rights to develop, manufacture, and commercialize CARDAMYST™ (etripamil) nasal spray in…

WSOP Poised to Return to ESPN Once Again

(AsiaGameHub) -   The World Series of Poker (WSOP), a poker powerhouse established by Benny Binion, and ESPN have announced a new streaming agreement on Thursday, confirming that the world's most prestigious and popular poker event will once again be broadcast on the network. ESPN to Bring Top-Tier Poker Action…

Xunce Technology’s Revenue Surges 449% Half-on-Half: Is a Structural Revaluation to a Hundred-Billion Market Cap Camp on the Horizon?

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - As AI accelerates into the inference era, enterprise-grade AI is achieving large-scale deployment, driving an exponential surge in Token consumption and ushering data demand into a new development stage. Against this backdrop, high-quality, structured and scenario-specific professional data has…

Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy

TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA® (lenvatinib), an orally available…

Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility

TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and MUFG Bank, Ltd. (“MUFG Bank”), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (TYO: 8306, “MUFG”) today announced a new Memorandum of Understanding (MoU) to expand NextGen, their business co-creation model. Building on…

Analogue 2025 Annual Results Profit Attributable to Owners of the Company Increases 23.5% to HK$167.0 Million

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results…

Behind the 449% Sequential Revenue Growth: Xunce Technology, Accelerates Its Embrace of the Token Economy

EQS via SeaPRwire.com / 27/03/2026 / 18:36 UTC+8 On March 27, 2026, Hong Kong-listed Xunce Technology (03317.HK) released its 2025 annual results, delivering a standout performance that captured market attention. The company achieved full-year revenue of RMB 1.285 billion, representing year-on-year growth of 103.28%, crossing the RMB 1 billion revenue threshold.…

ARK Invest Team Up with Kalshi for New Forecasting

(AsiaGameHub) -   A new collaboration between Kalshi and ARK Invest is propelling prediction platforms into the mainstream of professional investing, as companies seek enhanced tools to forecast an increasingly uncertain future. This partnership will offer an alternative perspective to conventional forecasting techniques, harnessing the wisdom of the crowd to…

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO:…

Modern Dental Group Announces 2025 Annual Results, Net Profit Surges 47.7% on Digitalization-Driven Operational Efficiency Gains

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million,…